Mr. Peter Colabuono is a Partner at Decheng Capital and has been with the firm since October 2016. He is currently serving as a board member and leading the operations of Ariagen. Mr. Colabuono is also a board director of ConjugateBio, Firefly Biologics and Solve Therapeutics. He previously served on the board of AADi Bioscience (NASDAQ: AADI), Checkmate Pharmaceuticals (acquired by Regeneron) and Velos Biopharma (acquired by Merck).
Mr. Colabuono brings finance, investment, transaction, operational and drug development expertise to Decheng, as well as a passion to find a cure for cancer and bring life-saving drugs to patients. Prior to joining Decheng, Peter held several operational roles, including business and corporate development, sales & marketing and company startups. As an Associate at Frazier Healthcare Ventures, he led the investment and company formation for Silvergate Pharmaceuticals (acquired by CutisPharma), a pediatric rare disease company that to date has launched four internally developed and proprietary products. As Vice President of Business Development & Managed Care and a member of the Operations Committee, Mr. Colabuono played essential role for the success of Silvergate. At Frazier, he was involved in and served as board observer for Calistoga Pharmaceuticals (acquired by Gilead Sciences), VentiRx (acquired by Celgene), Alnara Pharma (acquired by Eli Lilly) and Oceana Therapeutics (acquired by Salix), as well as several of the firm’s public investments. Prior to Frazier, he served in the Morgan Stanley and Cowen Healthcare Investment Banking groups. Mr. Colabuono holds a B.A. in Molecular Biology and Biochemistry from Dartmouth College, is an inventor and author on issued patents and journal articles, and he is active with the Head & Neck Cancer Alliance.